Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection

Summary

The main objective of this trial is to assess whether a sequential therapy strategy based on molecular antibiotic susceptibility testing (including clarithromycin and fluoroquinolone) for H. pylori infection will improve the eradication rate compared to an empirical therapy.

Timeline

Start

2022-09-20

Primary completion

2024-02

Completion

2024-02

Publications

• Lu K, Zou X, Lang C, Zang L, Yang X, Sang W, Wang J, Feng Q, Mu Y, Liu L, Xu C, Zhao J. Susceptibility-Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial. Microbiologyopen. 2026 Jun;15(3):e70313. doi: 10.1002/mbo3.70313.
• Lu K, Lang C, Zou X, Zang L, Sang W, Feng Q, Mu Y, Liu L, Xu C, Zhao J. Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial. Trials. 2023 Jun 19;24(1):413. doi: 10.1186/s13063-023-07457-z.

Drugs

Indications